This unusual question apparently had no influence on their serenity. Safe Harbor: This publication may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not clearly historical are forward-looking, and the words “predict,” “believe,” “believe,” “wait,” “estimate,” “plan,” “can,” and negative expressions of these expressions and the like generally identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Avadel`s own risk and could cause actual results to differ materially from those reflected in such forward-looking statements. These risks, uncertainties and contingencies include the risks associated with: (i) inability to finalize terms or otherwise fail to meet expectations regarding the date and conclusion of the final licensing agreement with Serenity, in circumstances that may require us to pay a $10,000,000 termination fee to Serenity; (ii) the amount of fees, fees, expenses and taxes associated with negotiating a final licensing agreement; (iii) the risks associated with the need to distract the management of the day-to-day operations of the business as a result of the negotiation of the final licensing agreement; and (iv) the other risks, uncertainties and contingencies described in the company`s U.S. listings. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year past December 31, 2016 (all listings are also available on the company`s website), including “Forward-Looking Statements” and “Factors,” including: our dependence on a small number of products and customers for the majority of our sales; the possibility that our Bloxiverz®, Vazculep® and Akovaz products® which are not protected by a patent, may be subject to considerable competition, resulting in a loss of market share or forcing us to reduce the prices we charge for these products; the possibility that we will not be able to conduct research and development of pipeline products that we are evaluating for possible fda application, in accordance with our “unauthorised” strategy, or that competitors may be able to complete the development of these products and seek FDA approval of these products; our dependence on third-party performance in strategic partnerships or alliances for the marketing of some of our products; the possibility that our products will not enter the commercial market or gain market acceptance; we need to invest considerable sums in research and development to remain competitive; our dependence on individual suppliers for the development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and supply certain raw materials used in our products; the ability of our competitors to develop and commercialize technologies or products that are more efficient or safer than ours, or to obtain regulatory approval and market such technologies or products before we do so; The intellectual property protection challenges that underpin our drug and other product delivery platforms; and our reliance on key personnel to implement our business plan.